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Abstract. Three-dimensional (3D) lung multicellular spheroids (MCS) in liquid-covered culture (LCC) and air-interface
culture (AIC) conditions have both been developed for the
evaluation of aerosol anticancer therapeutics in solution and
aerosols, respectively. The MCS were formed by seeding lung
cancer cells on top of collagen where they formed spheroids
due to the prevalence of cell-to-cell interactions. LCC MCS
were exposed to paclitaxel (PTX) in media whereas AIC
MCS were exposed to dry powder PEGylated phospholipid
aerosol microparticles containing paclitaxel. The difference
in viability for 2D versus 3D culture for both LCC and AIC
was evaluated along with the effects of the particles on lung
epithelium via transepithelial electrical resistance (TEER)

Correspondence to: Dr Samantha A. Meenach, 4 Present address:
Department of Chemical Engineering, University of Rhode Island,
205 Crawford Hall, 16 Greenhouse Road, Kingston, RI 02881, USA
E-mail: smeenach@uri.edu

Present address: 5Department of Pharmacy Practice and Science,
University of Arizona, Tuscon, AZ 85721, USA
*

Contributed equally

Abbreviations: 3D, three-dimensional; MCS, multicellular
spheroids; LCC, liquid covered culture; AIC, air-interface
culture; PTX, paclitaxel; TEER, transepithelial resistance; 2D,
two-dimensional; ECM, extracellular matrix; MPs, microparticles;
DPPC; dipalmitoylphosphatidylcholine; DPPE-PEG3k, dipalmitoyl
phosphatidylethanolamine methoxy(polyethylene glycol) 3000;
EE, encapsulation efficiency; PEG, poly(ethylene glycol); FBS,
fetal bovine serum; DMEM, Dulbecco’s Modified Eagle Medium;
NBD-PC, nitrobenzooxadiazole phosphatidylcholine, IC50, halfmaximal inhibitory concentration
Key words: multicellular spheroids, air interface culture, paclitaxel,
three-dimensional cell culture, lung cancer

measurements. For LCC and AIC conditions, the 3D spheroids
were more resistant to treatment with higher IC50 values for
A549 and H358 cell lines. TEER results initially indicated
a decrease in resistance upon drug or particle exposure,
however, these values increased over the course of several
days indicating the ability of the cells to recover. Overall,
these studies offer a comprehensive in vitro evaluation of
aerosol particles used in the treatment of lung cancer while
introducing a new method for culturing lung cancer MCS in
both LCC and AIC conditions.
Introduction
Patients in the United States die from lung cancer more than
any other individual cancer diagnosis (1). While surgical resection is the standard of care for early stage lung cancer, only
25% of patients have resectable disease at the time of diagnosis (2). As a result, current practice guidelines recommend
these patients be treated with a combination of chemotherapy
and radiation (3). In vitro cell culture models are a major factor
in analyzing the effectiveness of cancer therapeutics. In lung
cancer specifically, there are many characteristics of a tumor
that need to be altered in an in vitro cell culture model in order
for it to be as physiologically representative as possible. In
order to do this, many aspects of the cell culture methods have
to be improved. Specifically, a model that is three-dimensional
(3D), possesses a surrounding environment that is similar to
an in vivo tumor, yields proliferating cells, and is set up so
that cells can be exposed to air (as cancer cells are in the lung)
needs to be established.
To start, the use of 3D multicellular spheroids (MCS)
allows for a more tumor-like environment to evaluate chemotherapeutic drugs. MCS are small, tightly bound cellular
aggregates that tend to form when cells are maintained under
non-adherent conditions. These aggregates can range in size
from 20 µm up to 1 mm in diameter depending on the cell
type and growth conditions (4). Testing anticancer drugs in 3D
culture models will better simulate the tumor microenvironment and signaling pathways that are functional in tissues and
organs and can potentially provide a better correlation between
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in vitro screening and in vivo animal models (5). Tumor
spheroids are also considered an improved in vitro model to
mimic biological properties of micrometastases and vessel
distal regions of tumors because they retain the architecture
and many morphological and physiological characteristics of
their tumor counterparts (6).
MCS can mimic avascular in vivo tumors in that they have
diffusion limitations for many molecules, including oxygen,
and this inefficient mass transport leads to metabolic waste
accumulation inside the MCS so that they display a layer-like
structure comprised of a necrotic core surrounded by a viable
rim of cells (7,8). It is the center of a tumor that exhibits a
hostile microenvironment. This environment harbors the
most aggressive tumor cells, which will regenerate if they
are not eliminated. MCS have been effectively used to study
many types of therapeutics including nanoparticles, chemotherapeutics, and radiation where the MCS show significant
differences in response in comparison to two-dimensional
(2D) cell monolayers (9,10). Most chemotherapeutic drugs
affect actively proliferative tumor cells by either crosslinking
DNA or interfering with the formation of the mitotic spindle.
It is expected that these types of drugs would have a lesser
effect on 3D MCS, which have a large fraction of quiescent
cells. Also, the reduced diffusion of drugs through multiple
cell layers and increased expression of drug transporters can
result in drug resistance in MCS (11).
There are many methods for creating 3D MCS, the
most common of these include liquid overlay, embedding
in extracellular matrix (ECM) components, hanging drop,
micromolding, spinner flask, rotary culture, and centrifugation methods (7,12). Several of these methods have been
utilized in the development of 3D spheroid models of lung
cancer for the evaluation of solution-based anticancer therapeutics. For example, both A549 lung adenocarcinoma cells
and primary lung cancer cells have been grown via the liquid
overlay method on agarose (13,14) or poly(2-hydroxyethyl
methacrylate) (pHEMA) (6). Vertrees et al created spheroids
of a transformed cell line (BZR-T33) over several weeks in
a rotating wall vessel (15). A high throughput method of
spheroid creation was developed where H1650 lung cancer
cells were formed in mini-ports on a microchip (16). A549
spheroids were embedded in Matrigel™ which contains ECM
components and both A549 and H358 cells were embedded
in collagen for the formation of spheroids (5,17,18). Despite
these initial studies, they all pose disadvantages in the study
of aerosol therapeutics including drug diffusion limitations
through ECM-based matrices for the embedded method, challenges in implementation for the microchip method, the need
for specialized equipment for rotating wall vessel method, and
lack of air-interface conditions for the liquid overlay method.
The purpose of this current study was develop an in vitro
lung tumor spheroid model that could mimic in vivo tumor
shape, behavior, and environment more closely and effectively
and to observe the effects of both solution-based and aerosolbased therapeutics on this model. In liquid overlay culture,
culture plates are usually coated with a non-adhesive, partially
hydrophilic material to create a surface on which the cells,
once seeded, are more inclined to attach to each other than to
the culture surface, thereby initiating the formation of spheroids on the surface of the collagen. The spheroids are grown in

solution using a liquid-covered culture (LCC) method which
allows for the evaluation of drug in solution. Subsequently,
this system can be modified where the spheroids are formed
on collagen in Transwells® where the media is then removed
to allow the spheroids to be grown in air-interface culture
(AIC) conditions. This will allow for the evaluation of
aerosol-based therapeutics.
One of the current limitations in the evaluation of aerosolbased therapeutics for lung cancer is the lack of cell culture
models for the evaluation of their efficacy. The described work
allows for the evaluation of effectiveness of such therapeutics
on 2D cells and 3D spheroids grown in AIC conditions as
well as the evaluation of the safety of these systems using
transepithelial resistance (TEER) analysis. When grown using
AIC, primary cell layers resemble the native epithelium to a
greater extent than cells grown using LCC (19). Furthermore,
the growth of spheroids in AIC conditions is more physiologically representative than LCC and allows the direct testing of
aerosol therapeutics on the cells rather than having to dissolve/
disperse them in solution. TEER is a measurement of the
electrical resistance across a cell monolayer and this measurement can be used to analyze the permeability of the cells in
a monolayer. TEER reduction has been used as an indication
of adverse effects of model toxicants and inhaled delivery
vehicles and corresponds well with standard toxicological
tests (20,21). Ensuring that there is no significant change in
the permeability of lung cancer cells is important in showing
the safety of the aerosol therapeutic. Calu-3 lung cells have
already been established for use in TEER studies for both
LCC and AIC conditions (19,22,23).
Paclitaxel (PTX) was selected as the model therapeutic
as it is widely used in the treatment of non-small cell lung
cancer via intravenous delivery (24,25) and is being investigated in aerosolized formulations for the treatment of
lung cancer (26-28). Our group has developed dry powder
PEGylated phospholipid microparticles containing PTX that
show optimized aerodynamic diameters, release, and aerosol
dispersion properties (29,30). These were selected to act as
the model for an aerosol treatment for lung cancer for the
validation of the AIC 3D MCS model. Overall, this study
outlined the pertinent physicochemical characteristics of the
dry powder aerosol microparticles, which were used and the
in vitro characterization of both the dry powders and PTX in
solution. This particular characterization included evaluating
the activity of the PTX encapsulated in the particles, uptake of
the particles into A549 cells, development of the lung MCS in
LCC and AIC conditions, efficacy of the solution-based and
aerosol particle treatments, and safety of the aerosol particles
using TEER. These studies may potentially act as a model for
the more comprehensive evaluation into the efficacy and safety
of aerosol particles in vitro prior to more time-consuming and
expensive in vivo experiments.
Materials and methods
Materials. Fetal bovine serum (FBS), penicillin-streptomycin
solution and trypsin/EDTA were obtained from American
Type Culture Collection (ATCC, Manassas, VA). Calcein AM,
ethidium homodimer-1, Dulbecco's modified Eagle's medium
(DMEM), sodium pyruvate, Fungizone®, Lysotracker ® Red,
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Hoescht 3342, and L-glutamine were obtained from Invitrogen
(Grand Island, NY, USA). DMSO and resazurin sodium salt
were obtained from Sigma-Aldrich (St. Louis, MO, USA)
and collagen I (rat tail) was from BD Biosciences (San Jose,
CA, USA). Synthetic dipalmitoylphosphatidylcholine (DPPC,
molecular weight (MW): 734.039 g/mol; >99% purity) and
dipalmitoylphosphatidylethanolamine-methoxy(polyethylene
glycol) (DPPE-PEG3k, MW 3716.304 g/mol which corresponds to 3000 molecular weight poly(ethylene glycol) length
per compound; >99% purity) were obtained from Avanti Polar
Lipids (Alabaster, AL, USA). Paclitaxel was obtained from LC
Laboratories (Woburn, MA, USA; 99.5% purity). All materials
were used as received.
Cell lines and culturing conditions. H358 (bronchioalveolar
carcinoma) and A549 (lung adenocarcinoma) cells were
obtained from ATCC and were cultured in medium comprised
of DMEM, 10% FBS, 4 mM L-glutamine, 1 mM sodium pyruvate, 0.25 µg/ml Fungizone, 100 IU penicillin, and 100 µg/ml
streptomycin. The cells were grown at 37˚C and 5% CO2 in a
humidified atmosphere.
Dry powder particle synthesis and PTX loading. Dry aerosol
powders were synthesized via spray drying as described previously by our group (29,30). PEGylated phospholipid particles
were made by mixing DPPC and DPPE-PEG3k (95:5 molar
ratio) with 1, 5, 25, and 50 mol% paclitaxel relative to the total
phospholipid amount in methanol (hereby abbreviated as 1%
PTX MPs, 5% PTX MPs, 25% PTX MPs, and 50% PTX MPs,
respectively, where MPs refers to microparticles). The solutions
were then spray dried to produce particles approximately 1 µm
in diameter (30). UV-Vis was used to determine the amount
of paclitaxel loaded into the formulated particle systems. The
particles were dissolved in known quantities of methanol prior
to analysis. The absorbance intensity was measured at 227 nm
using a Synergy Mx BioTek microplate reader. The paclitaxel
encapsulation efficiency (EE) and loading was calculated as
follows:
Actual mass of PTX
EE = ----------------------------------------- x 100%
Initial mass of PTX
Actual mass of PTX
Drug loading = --------------------------------------Mass of particles

(1)
(2)

Particle internalization/Uptake study. A549 cells were
exposed to 25% PTX MPs loaded with 1 mol% nitrobenzoxadiazole phosphatidylcholine (NBD-PC) to allow for fluorescent
imaging of the particles. Cells/well (60,000) were seeded into
an 8-well chamber slide and were left to attach for 24 h. They
were then exposed to 1 mg/ml of particles in media for 6 and
24 h. After exposure, the cells were washed with a 200 mM
glycine solution to remove any non-internalized particles and
were then stained with 7.5 nM Lysotracker Red and 10 µM
Hoescht 33342 prior to live imaging. Imaging was completed
using a Nikon Eclipse 80i microscope.
A549 viability/Particle activity study. The activity of the
paclitaxel present in the particles was evaluated by exposing
A549 cells to various concentrations of PTX-loaded micro
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particles and free (raw) paclitaxel. A549 cells were seeded at
3,000 cells/well in 96-well plates for 48 h followed by exposure to PTX-loaded particles or PTX diluted in DMSO from
0.0001 to 1 µM in media. The PTX was initially dissolved in
DMSO at its highest solubility and then diluted with media
for further PTX concentrations. The amount of DMSO was
kept constant at 0.1% v/v for all PTX concentrations (also the
control), including for PTX-loaded microparticle samples. A
control of particles without PTX was also evaluated using the
same amount of particles as the particle system with the lowest
concentration of PTX. At 72 h after exposure, the cells were
exposed to 2 mM of resazurin for 3 h. The fluorescence intensity of the resulting resorufin was measured using a Synergy
Mx BioTek microplate reader at 579/584 nm (excitation/emission) wavelengths. The relative viability was then evaluated
as the fluorescence intensity of the sample divided by the
fluorescence intensity of control cells (no treatment).
Two-dimensional cell culture evaluation of paclitaxel and
paclitaxel-loaded dry powder particles. Cells were grown in
both air-interface culture (AIC) and liquid-covered culture
(LCC) conditions to determine the half-maximal inhibitory
concentration (IC50) for 2D culture conditions. For the LCC
condition, H358 and A549 cells were seeded in 96-well plates
at 7,500 and 3,000 cells/well, respectively. After 48 h, the cells
were exposed to PTX (0.0001 to 1 µM) where all PTX solutions contained 0.1% (v/v) DMSO in medium to aid in PTX
solubility. For AIC conditions, H358 and A549 cells were
seeded in Transwells (0.4 µm polyester membrane, 12 mm,
12-well plate) at 22,000 and 14,000 cells/well, respectively,
with 0.5 ml media on the apical side and 1.5 ml of media on
the basolateral side of the Transwell. At 24 h after seeding,
media was removed from the apical side and the basolateral
side was reduced to 0.5 ml to induce AIC conditions. After a
further 24 h, the cells were exposed to 1 mg of each particle
type (blank, 1, 5, and 25% PTX MPs) using a 1 ml syringe
and 21G needle to aerosolize the particles onto the cells. At
72 h after exposure to PTX, the viability of the cells was
determined via a resazurin (viability) assay as described
above (0.5 ml of media was added to the AIC cells prior to
the analysis). IC50 values were determined using SigmaPlot
12.0 software.
Three-dimensional multicellular spheroid (MCS) formation. MCS were formed on type I rat tail collagen which was
used because of its non-adhesive nature to more prominently
induce cell-to-cell interactions. LCC and AIC conditions were
induced by seeding cells onto collagen in 24-well plates and
Transwell, respectively, and the visualization of this process
can be seen in Fig. 1. Collagen solution was mixed according
to the manufacturer's instructions. A 2.1 mg/ml collagen solution was pipetted into the plates and allowed to solidify at 37˚C
in an incubator for 30 min. H358 and A549 cells were seeded
at 10,000 cells/well and 7,500 cells/well, respectively (0.5 ml
media and cells on the apical and 1.5 ml of media on the basolateral side of the Transwells for AIC). For AIC conditions, the
media was removed from the apical side after 24 h. The size
and morphology of the spheroids was determined via bright
field imaging. During their growth and formation, the MCS
were imaged daily and their diameter was analyzed using
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Table I. PEGylated phospholipid microparticle systems containing paclitaxel, actual PTX encapsulation efficiency (EE),
actual loading of PTX and PTX IC50 values corresponding to
dose-response curve.

Figure 1. Schematic depicting liquid overlay culture (LCC) condition versus
AIC conditions in the culturing of lung cancer multicellular spheroids (MCS).

NIS-Elements software. Both to PTX exposure as well as at
the end of PTX exposure, the spheroids were stained using
calcein AM and ethidium homodimer-1 and imaged to show
the presence in live and dead cells, respectively.
Three-dimensional MCS evaluation of paclitaxel and paclitaxel-loaded dry powder particles. The cells were grown until
spheroid formation was evident (4 days for H358 and 9 days
for A549 cells). The evaluation of the effect of PTX on MCS
was determined by exposing the cells to PTX utilizing the
LCC condition and AIC condition where the drug was applied
to the air interface of the cells via phospholipid dry powder
aerosol containing PTX. For the LCC condition, the MCS
were exposed to 0.0001 to 1 µM PTX and for AIC condition,
the MCS were exposed to blank, 1, 5 and 25% PTX MPs as
described above. After 72 h, viability was determined using the
resazurin assay. IC50 values were determined using SigmaPlot
12.0 software.
Transepithelial electrical resistance (TEER) analysis on lung
cell monolayers. TEER evalution was completed using an
EVOM2 epithelial voltammeter and 12 mm Endohm culture
cup from World Precision Instruments (Sarasota, FL, USA).
Calu-3 cells were seeded at 250,000 cells/well in Transwells.
To induce AIC conditions, the media was removed from the cell
monolayer after 24 h and was replaced and removed for TEER
measurement only. TEER values were measured every other
day for both AIC and LCC conditions. Upon reaching resistance equilibrium (after 5 days), the monolayer was exposed
to phospholipid dry powder particles with or without PTX
(AIC condition) as well as PTX in media (LCC condition). The
resistance of the monolayer was again measured 2, 4, 24, 48,
72, 96 and 120 h after PTX or particle exposure. The reported
resistance values are the actual resistance less the resistance
due to a blank Transwell.
Results and Discussion
Dry powder PEGylated phospholipid microparticles (MPs)
were used as a model system to demonstrate the validity of
a 3D air-interface culture (AIC) multicellular spheroid model
in the evaluation of aerosol lung therapeutics. The particles

System

Actual
PTX EE
(wt %)

PTX Loading
(mg PTX/mg
particles)

PTX IC50
(µM)

Raw PTX
1% PTX MPs
5% PTX MPs
25% PTX MPs
50% PTX MPs

NA
99.1±2.2
96.6±1.2
95.9±3.1
98.2±2.1

NA
0.010±0.001
0.059±0.007
0.268±0.009
0.512±0.008

0.0346
0.0053
0.0047
0.0030
0.0028

were loaded with paclitaxel (PTX) at 1, 5, 25, and 50 mol%.
Our previous work shows these particles to be approximately
1 µm in diameter (30). PTX encapsulation efficiencies (EE)
were high for all particle systems (at least 96.6 weight %) and
the actual EE values are listed along with the actual PTX loadings (mg PTX/mg particles) in Table I. This is ideal for aerosol
drug delivery systems especially as it allows for the maximum
amount of drug loading in the particle, allowing for minimal
excess powder delivery while still maintaining optimal treatment properties.
The effect of the particles on lung cells was initially
evaluated via both uptake and liquid-covered culture (LCC)
viability studies. A549 cells were exposed to 1 mg/ml of 50%
PTX MPs (the highest PTX loading) containing fluorescent
NBD in media for 6 and 24 h. Fig. 2 includes representative combined fluorescent micrographs of cells exposed to
particles and the subsequent controls. At 6 h, there was some
uptake of particles evident (green) with a significant amount
of lysosome staining (red) where the nuclei were stained blue.
The morphology and staining was similar for the control cells
at 6 h in comparison to the cells exposed to particles. After
the 24 h particle exposure, there was also particle uptake
evident, however, there were much fewer cells attached to
the slides in comparison to the control. This is likely due to
the significant amount of cell death that would have occurred
for this exposure time and PTX concentration. Overall, these
results demonstrate the capability of the particles to internalize within lung epithelial cells, potentially enhancing the
delivery of paclitaxel.
The activity of PTX in the particles after spray drying was
evaluated by dispersing the particles in media and exposing
A549 cells to various concentrations of PTX for 72 h to
produce a dose-response curve. The viability for blank particles (without PTX) was 99±2% which was not significantly
different from the control (p>0.9). While the resulting IC50
value of raw PTX (no spray drying) was 0.0346 µM, the IC50
values for the particles ranged from 0.0028 to 0.0053 µM for
the particle systems as seen in Table I. This 10-fold decrease
in IC50 values could be due to the uptake of the particles
into A549 cells and subsequent PTX release or as a result
of paclitaxel binding with the serum present in the media,
decreasing the effective dose of raw paclitaxel in media. In
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Figure 2. Representative fluorescent micrographs of A549 cells used in PEGylated phospholipid microparticle uptake studies where (A and B) are after 6 h of
exposure, (C and D) are after 24 h of exposure. Cells in (A and C) were exposed to 1 mg/ml of 25% PTX MPs whereas (B and D) are control cells. Blue, red,
and green fluorescent staining represent the cell nuclei, cell cytoskeleton, and microparticles, respectively. Scale bar, 50 µm.

Figure 3. Representative micrographs of an air-interface culture (AIC) condition 3D spheroid formation including bright field images and final day fluorescent
images (with respect to time) where green cells stained with calcein are alive and red cells stained with ethidium homodimer-1 are dead. Scale bar, 200 µm.

the end, these results demonstrate that paclitaxel retains its
efficacy and activity against lung cancer cells after spray
drying and increases the efficacy by its targeted delivery to
the cells.
A 3D lung cancer multicellular spheroid (MCS) model was
formed by seeding either A549 or H358 cells onto collagen in
either liquid-covered culture (LCC) or air-interface culture
(AIC) conditions. Fig. 3 shows micrographs of the resulting
3D spheroids grown in AIC conditions with time. For H358
cells, spheroids formed fairly quickly after seeding (within
two days) with a distribution of sizes whereas A549 form
loose spheroid aggregates only after 9 days of cell culture.

Spheroids grown in LCC conditions were visually the same
in size and morphology as those in AIC conditions for both
cell lines (data not shown). The spheroids were fluorescently
stained to show cell viability and death after 6 or 12 days of
culturing (H358 and A549 cells, respectively), which is the
final growth time after treatment with PTX or PTX-loaded
MPs. H358 cells were almost entirely alive (green) whereas
A549 cells showed some cell death (red). These results indicate
that the spheroids were able to maintain their growth profiles
and stay alive with nutrient transfer through the collagen layer
throughout their growth and treatment with paclitaxel. While
efficacy experiments were completed on both cell lines, it may
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Figure 4. Spheroid diameter/growth curves for (A) H358 and (B) A549 3D spheroids in LCC conditions during spheroid formation and after treatment with
paclitaxel in media.

Figure 5. Dose-response curves of lung cancer cell lines exposed to PTX and PTX-loaded aerosol microparticles in the following conditions: (A) A549 cells
exposed to raw PTX in LCC conditions, (B) H358 cells exposed to raw PTX in LCC conditions, (C) A549 cells exposed to PTX-loaded microparticles in AIC
conditions, and (D) H358 cells exposed to PTX-loaded microparticles in AIC conditions.

be that H358 cells provide a better model for fully formed,
spherical spheroids grown on collagen in the evaluation of
lung anticancer therapeutics (Fig. 4).
To provide a baseline comparison to the 3D MCS models
(both AIC and LCC), PTX and PTX-loaded particles were
also evaluated using 2D-cultured cells in both LCC and
AIC conditions, respectively. Dose-response curves for both

cell types and both 2D and 3D culturing conditions can be
seen in Fig. 5. The actual PTX dose for the AIC studies was
determined by using the actual amount of PTX loaded in the
particles (Table I) and the amount of powder dose provided to
each sample/well of cells (1 mg) resulting in units of mg/dose.
The resulting IC50 values can be found in Table II. For LCC
conditions, 3D cells exhibited a delayed lag in response on

INTERNATIONAL JOURNAL OF ONCOLOGY 48: 1701-1709, 2016
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Figure 6. Fluorescent micrographs of spheroids grown in LCC conditions on the final day of raw PTX treatment. (A-F) are H358 cells exposed to 0, 0.0001,
0.001, 0.01, 0.1 and 1 µM in corresponding order. (G-L) are A549 cells exposed to 0, 0.0001, 0.001, 0.01, 0.1 and 1 µM in corresponding order. Scale bar, 200 µm.

Figure 7. Transepithelial electric resistance (TEER) evaluation of Calu-3 monolayers grown in LCC (A) and AIC (B) conditions after exposure to paclitaxel
and paclitaxel-loaded microparticles, respectively. Approximately 1 mg/well of liposphere particles were applied to each AIC sample.

the dose-response curve corresponding to higher IC50 values
for both cell types in comparison to 2D cells (0.0783 and
0.0103 µM PTX for H358 cells, 0.4065 and 0.0878 µM PTX
for A549 cells for 3D and 2D, respectively). These results
indicate that spheroids are more resistant to PTX treatment in
media, likely due to transport limitations into the spheroids
providing a natural protection to the cells. For AIC conditions, A549 3D spheroids were more resistant to PTX-loaded
PEGylated phospholipid MPs in comparison to 2D cells
(991.02 versus 37.78 µg PTX, respectively). Similarly, H358
3D spheroid were also more resistant to PTX-loaded MPs in
comparison to 2D where the IC50 values for AIC conditions
were 5.29 and 20.03 µg for 2D and 3D, respectively. These
results demonstrate the potential importance of evaluating
lung anticancer therapeutics in 3D cell culture, as there is a
significant difference in cellular responses between 2D and
3D systems. Furthermore, the culturing of lung cancer cells
in AIC conditions as the resulting cellular responses may
provide a more physiologically relevant model for anticancer
therapeutic evaluation when validated against in vivo models
and/or human clinical trials. In particular, the results reported
for AIC evaluation were in µg/dose, thereby allowing for a
simple determination of the dose that should be given to a
patient in terms of mg/kg via direct inhalation to the lung.
The size of the spheroids was evaluated over time both
before and after treatment in LCC conditions to determine
the effect of PTX exposure on the spheroid morphology as

Table II. IC50 values for A549 and H358 2D cells and 3D
spheroids in both LCC and AIC conditions.
		 LCC
Culture
PTX IC50
Cells
condition
(µM)
H358
A549

2D
3D
2D
3D

0.013
0.084

0.084
0.334

AIC
PTX IC50
(µg/dose)
20.0
39.2

5.3
991.0

seen in Fig. 6. For H358 cells, the spheroid sizes increased
with time and were approximately 150 µm in size after 4 days,
which is when they were treated with PTX. At 72 h after PTX
exposure, the spheroid size decreased significantly for cells
exposed to 0.01, 0.1 and 1 µM of PTX whereas those exposed
to 0.0001 and 0.001 µM PTX did not differ significantly from
the control (p<0.05). Thus, there is a threshold value at which
spheroid dissociation may occur when treating with PTX.
A549 spheroids increased in size with time, reaching approximately 60 µm in diameter after 9 days, which is when they
were treated with PTX. At 72 h after treatment, the spheroid
sizes decreased for cells exposed to 0.01, 0.1 and 1 µM as with
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the H358 cells and remained the same size when exposed to
0.0001 and 0.001 µM of PTX.
Transepithelial resistance (TEER) was evaluated by
exposing 2D Calu-3 cells in AIC conditions to PEGylated
phospholipid MPs containing PTX and LCC conditions to
PTX in media. Fig. 7 shows the measured resistance of the
Calu-3 cells after the described treatments up to five days
where the initial treatment was done after the cells reached
resistance equilibrium, which are similar to those previously
reported in literature (31). For LCC cells, the resistance
continued to increase for all systems up to five days, however,
for cells exposed to 0.01 and 1 µM PTX the resistance was
initially stagnant before recovering and increasing with
time. For AIC cells exposed to MPs, the resistance initially
decreased for all cells (including the control) which is likely
due to the addition of media, which could dilute any mucin
present on the cell layers, thereby decreasing the resistance.
Cells exposed to 25% PTX exhibited the most significant
decrease in resistance along with those exposed to 5% PTX,
however, all samples recovered to the control resistance
after 5 days (no significant difference, p<0.05). These results
demonstrate that while dry powder PEGylated phospholipid
MPs used for aerosol delivery may initially have a detrimental effect on lung tissue, that it will subsequently recover
and likely only result in temporary morbidity.
Overall, the given results demonstrate the validity of using
an AIC 3D spheroid model in the evaluation of lung anticancer therapeutics, which is the first time this has been done.
PEGylated phospholipid microparticles loaded with paclitaxel
were evaluated by cells grown in AIC conditions, whereas
PTX in media was evaluated by cells in 3D conditions. The
actual PTX loading and resulting activity of the PTX in the
particles was favorable (high loading and increased efficacy
with particle delivery). Furthermore, the difference in cellular
response in terms of 2D versus 3D and AIC versus LCC
culturing conditions was demonstrated. Finally, the safety
of the MPs was demonstrated by TEER evaluation. These
methods provide the means to more thoroughly characterize
dry powder aerosol particles (AIC conditions) and solutionbased aerosol particles (LCC conditions) for lung cancer
aerosol therapeutics.
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